Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): Additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study

Clinical Therapeutics

Volumn 31, Issue 4, 2009, Pages 751-761

  Emkey, Ronald ^a   Delmas, Pierre D ^b   Bolognese, Michael ^c   Borges, Joao Lindolfo C ^d   Cosman, Felicia ^e   Ragi Eis, Sergio ^f   Recknor, Christopher ^g   Zerbini, Cristiano A ^h   Neate, Colin ⁱ   Sedarati, Farhad ^j   Epstein, Solomon ^k  

^a RADIANT RESEARCH   (United States)

^b UNIVERSITÉ DE LYON   (France)

^c Bethesda Health Research   (United States)

^d UNIVERSIDADE CATÓLICA DE BRASÍLIA   (Brazil)

^e HELEN HAYES HOSPITAL   (United States)

^f CEDOES Diagnostico e Pesquisa   (Brazil)

^g United Osteoporosis Centers   (United States)

^h HOSPITAL HELIÓPOLIS   (Brazil)

ⁱ ROCHE PRODUCTS LTD   (United Kingdom)

^j HOFFMANN LA ROCHE INC   (United States)

^k MOUNT SINAI SCHOOL OF MEDICINE   (United States)

more..

Author keywords

alendronate; bisphosphonates; bone markers; bone mineral density; ibandronate; postmenopausal osteoporosis

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; IBANDRONIC ACID; PLACEBO; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GREATER TROCHANTER; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SERUM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COLLAGEN TYPE I; DIPHOSPHONATES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 65549105437     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.04.018     Document Type: Article

References (24)

1. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348 (1996) 1535-1541
2. Cummings S.R., Black D.M., Thompson D.E., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 280 (1998) 2077-2082
3. Harris S.T., Watts N.B., Genant H.K., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282 (1999) 1344-1352
4. Reginster J., Minne H.W., Sorensen O.H., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11 (2000) 83-91
5. Chesnut III C.H., Skag A., Christiansen C., et al., the Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19 (2004) 1241-1249
6. Brown J.P., Kendler D.L., McClung M.R., et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 71 (2002) 103-111
7. Schnitzer T., Bone H.G., Crepaldi G., et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 12 (2000) 1-12
8. Miller P.D., McClung M.R., Macovei L., et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-Year results from the MOBILE study. J Bone Miner Res 20 (2005) 1315-1322
9. Fosamax prescribing information. http://www.merck.com/product/usa/pi_circulars/f/fosamax/fosamax_pi.pdf Accessed April 16, 2009
10. Actonel prescribing information. http://www.actonel.com/prescribinginformation.jsp" Accessed April 16, 2009
11. Emkey R., Koltun W., Beusterien K., et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: The Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 21 (2005) 1895-1903
12. Hadji P., Minne H., Pfeifer M., et al. Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with post-menopausal osteoporosis: A randomized, crossover study (BALTO II). Joint Bone Spine 75 (2008) 303-310
13. Rosen C.J., Hochberg M.C., Bonnick S.L., et al., the Fosamax Actonel Comparison Trial Investigators. Treatment with once-weekly alendronate 70 mg compared with once-weekly rised-ronate 35 mg in women with post-menopausal osteoporosis: A randomized double-blind study. J Bone Miner Res 20 (2005) 141-151
14. Sebba A.I., Bonnick S.L., Kagan R., et al., the Fosamax Actonel Comparison Trial Investigators. Response to therapy with once-weekly alendronate 70 mg compared to once-weekly ris-edronate 35 mg in the treatment of postmenopausal osteoporosis [published correction appears in CurrMed Res Opin. 2005;21;325]. Curr Med Res Opin 20 (2004) 2031-2041
15. Miller P.D., Epstein S., Sedarati F., and Reginster J.Y. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopaus-al osteoporosis: Results from the head-to-head MOTION study. Curr Med Res Opin 24 (2008) 207-213
16. Cosman F., Borges J.L., and Curiel M.D. Clinical evaluation of novel bisphos-phonate dosing regimens in osteoporosis: The role of comparative studies and implications for future studies. Clin Ther 29 (2007) 1116-1127
17. The World Medical Association (WMA). Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects including the note of clarification on paragraph 30 added by the WMA General Assembly, Tokyo (2004). http://www.wma.net/e/policy/b3.htm Accessed April 15, 2009
18. Sebba A.I. Significance of a decline in bone mineral density while receiving oral bisphosphonate therapy. Clin Ther 30 (2008) 443-452
19. Bauer D.C., Black D.M., Garnero P., et al., the Fracture Intervention Trial Study Group. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The Fracture Intervention Trial. J Bone Miner Res 19 (2004) 1250-1258
20. Wasnich R.D., and Miller P.D. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85 (2000) 231-236
21. Hochberg M.C., Greenspan S., Wasnich R.D., et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87 (2002) 1586-1592
22. Papapoulos S.E., and Schimmer R.C. Changes in bone remodeling and antifracture efficacy of intermittent bisphosphonate therapy: Implications from clinical studies with iban-dronate. Ann Rheum Dis 66 (2007) 853-858
23. US Dept of Health and Human Services. Bone health and osteoporosis: A report of the Surgeon General (2007). http://www.surgeongeneral.gov/library/bonehealth/ Accessed April 15, 2009.
24. Reginster J.Y., Abadie E., Delmas P., et al. Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men. Osteoporos Int 17 (2006) 1-7